Please assess the completion status of the following clinical trial:

Trial Title: Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-70 years old;~* Patients with cervical cancer who have not undergone surgery for initial treatment, the international union of gynecology and obstetrics (FIGO) stage IIb-IIIb; Squamous cell carcinoma diagnosed by histopathology.~* The expected survival time was more than 8 months; the Eastern Cooperative Oncology Group (ECOG) performance status score≤1;~* Bone marrow hematopoietic function is normal before treatment (ANC≥1.8×109/L, PLT≥100×109/L, Hb≥90g/L, WBC≥4.0×109/L);~* No obvious abnormality in the ECG examination, and no obvious cardiac dysfunction;~* All patients must agree to take effective contraceptive measures during the study period and within 6 months after stopping treatment, and women of childbearing age must have a negative urine pregnancy test prior to treatment administration;~* The subjects voluntarily participate in this clinical trial and sign an informed consent form.~Exclusion Criteria:~* Those who refuse to accept PEG-rh-G-CSF;~* Currently conducting clinical trials of other drugs;~* Uncontrolled infection before treatment, body temperature ≥ 38℃;~* Chronic diseases of the heart, kidney, liver or other important organs;~* Patients with severe uncontrolled diabetes;~* Pregnant or lactating female patients;~* Persons with allergic diseases or allergic constitution, or allergic to this product or other biological products derived from genetically engineered E. coli;~* Suspected or confirmed drug, substance or alcohol abuse;~* Severe mental or neurological disorders that affect informed consent and/or adverse reaction presentation or observation;~* HIV-positive people;~* Patients requiring radiation therapy for the retroperitoneal or inguinal region.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- experimental group (Type: EXPERIMENTAL): patients used 6 mg PEG-rhG-CSF prophylactically after chemotherapy
- control group (Type: PLACEBO_COMPARATOR): patients did not use PEG-rhG-CSF for prevention and were given 5 ug/kg rhG-CSF when ANC\<1✕109/L

Based on this trial design, predict the completion outcome and termination type (if applicable).